Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neuroendocrine neoplasms of the breast: a multicenter retrospective Italian study.
Baldelli R, Franco M, Renzelli V, DE Fata R, Visca P, Macciomei MC, Fabi A, Rossi V, Faggiano A, Rizza L, Rota F, Appetecchia M, Vecchione A, Lania A, Antonini S, Botticelli A, Verrico M, D'Amati G, Pignataro MG, Cerbelli B, Bianchi A, LA Salvia A, Zuppi P, Rindi G; SIE (Società Italiana di Endocrinologia). Baldelli R, et al. Among authors: fabi a. Minerva Endocrinol (Torino). 2024 Dec 11. doi: 10.23736/S2724-6507.24.04200-3. Online ahead of print. Minerva Endocrinol (Torino). 2024. PMID: 39660883
An Integrated Care Approach to Improve Well-Being in Breast Cancer Patients.
Fabi A, Rossi A, Mocini E, Cardinali L, Bonavolontà V, Cenci C, Magno S, Barberi V, Moretti A, Besharat ZM, Iolascon G, Baldari C, Ferretti E, Botticelli A, Paris I, Scambia G, Migliaccio S. Fabi A, et al. Curr Oncol Rep. 2024 Apr;26(4):346-358. doi: 10.1007/s11912-024-01500-1. Epub 2024 Feb 24. Curr Oncol Rep. 2024. PMID: 38400984 Free PMC article. Review.
Male breast cancer: a multicenter study to provide a guide for proper management.
Lissidini G, Nicosia L, Sargenti M, Cucchi MC, Fabi A, Falco G, Gardani M, Grilz G, Maugeri I, Murgo R, Neri A, Pellini F, Sensi C, Scomersi S, Taffurelli M, Bagnardi V, Oriecuia C, Pagan E, Sangalli C, Dessena M, Veronesi P, Galimberti V. Lissidini G, et al. Among authors: fabi a. Breast Cancer Res Treat. 2024 Nov;208(1):29-40. doi: 10.1007/s10549-024-07380-0. Epub 2024 Jun 19. Breast Cancer Res Treat. 2024. PMID: 38896332
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review.
Zambelli A, Cortesi L, Gaudio M, Arpino G, Bianchini G, Caruso F, Cinieri S, Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D, Gennari A, Gori S, Grandi G, Guarneri V, Klinger M, Livi L, Marchiò C, Palumbo I, Panizza P, Pravettoni G, Pruneri G, Puglisi F, Sapino A, Tinterri C, Turchetti D, De Laurentiis M. Zambelli A, et al. Among authors: fabi a. Cancer Treat Rev. 2024 Nov;130:102815. doi: 10.1016/j.ctrv.2024.102815. Epub 2024 Aug 21. Cancer Treat Rev. 2024. PMID: 39208751 Free article. Review.
The role of body composition in neurological and hematologic toxicity in a retrospective analysis of 120 breast cancer patients undergoing neoadjuvant chemotherapy: the COMBOTOX study.
Di Leone A, Filippone A, Maggiore C, Rossi MM, Rossi C, Di Micco A, Forcina L, Franco A, Ionta L, Fabi A, Paris I, Scardina L, Sanchez AM, Pafundi PC, Franceschini G, Masetti R, Magno S. Di Leone A, et al. Among authors: fabi a. Breast Cancer Res Treat. 2024 Dec 4. doi: 10.1007/s10549-024-07553-x. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39630164
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S, Terrenato I, Porru M, Di Vito S, Rizzo A, D'Angelo C, Petti E, Dinami R, Maresca C, Di Benedetto A, Palange A, Mulè A, Santoro A, Palazzo A, Fuso P, Stoppacciaro A, Vici P, Filomeno L, Di Lisa FS, Arcuri T, Krasniqi E, Fabi A, Biroccio A, Zizza P. Iachettini S, et al. Among authors: fabi a. J Exp Clin Cancer Res. 2024 Mar 9;43(1):75. doi: 10.1186/s13046-024-02998-w. J Exp Clin Cancer Res. 2024. PMID: 38459559 Free PMC article.
Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis.
Caputo R, Buono G, Piezzo M, Martinelli C, Cianniello D, Rizzo A, Pantano F, Staropoli N, Cangiano R, Turano S, Paris I, Nuzzo F, Fabi A, De Laurentiis M. Caputo R, et al. Among authors: fabi a. Front Oncol. 2024 Mar 26;14:1362641. doi: 10.3389/fonc.2024.1362641. eCollection 2024. Front Oncol. 2024. PMID: 38595817 Free PMC article.
Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs).
Dri A, Arpino G, Bianchini G, Curigliano G, Danesi R, De Laurentiis M, Del Mastro L, Fabi A, Generali D, Gennari A, Guarneri V, Santini D, Simoncini E, Zamagni C, Puglisi F. Dri A, et al. Among authors: fabi a. Cancer Treat Rev. 2024 Feb;123:102672. doi: 10.1016/j.ctrv.2023.102672. Epub 2023 Dec 14. Cancer Treat Rev. 2024. PMID: 38118302 Free article. Review.
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.
Poggio F, Blondeaux E, Tagliamento M, Perachino M, Nardin S, Conte B, Giuliano M, Arpino G, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Magnolfi E, Gasparro S, Fabi A, Garrone O, Alicicco MG, Urracci Y, Poletti P, Correale P, Molinelli C, Fozza A, Puglisi F, Colantuoni G, Fregatti P, Boni L, Lambertini M, Del Mastro L. Poggio F, et al. Among authors: fabi a. ESMO Open. 2024 Aug;9(8):103650. doi: 10.1016/j.esmoop.2024.103650. Epub 2024 Aug 8. ESMO Open. 2024. PMID: 39121814 Free PMC article. Clinical Trial.
330 results